Research Reference

Klotho

Anti-aging protein & KP1/KP6 peptides — preclinical-only, no human dosing established

Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.

Klotho is a protein named after the Greek fate-spinner Clotho, discovered in 1997 when mice overexpressing it were found to live roughly 20–30% longer. It exists mainly as membrane-bound α-Klotho — a co-receptor for FGF23 that regulates phosphate and calcium homeostasis — and soluble/circulating α-Klotho (s-Klotho), which carries systemic anti-aging effects. Klotho levels decline with age and in chronic kidney disease, diabetes, and Alzheimer's disease; low circulating levels correlate with higher mortality.

The research peptides: KP1 and KP6

Most "Klotho peptide" discussion refers to KP1 and KP6, short synthetic peptides derived from the Klotho protein and studied in animal models of kidney disease. No human clinical trials have been conducted with KP1 or KP6, and no human dosing has been established.

Why this guide is flagged preclinical-only

KP1 and KP6 are research reagents, not pharmaceutical products or dietary supplements.
All dosing data comes from rodent studies; human pharmacokinetics (metabolism, distribution, receptor binding) are completely unknown.
The IV and chronic-infusion routes used in studies do not translate cleanly to subcutaneous injection.
The cognitive data show an inverted dose-response — low dose enhanced cognition, high dose did not — which complicates any attempt to extrapolate a dose.
Products marketed as "Klotho supplements" generally do not contain actual Klotho-derived peptides.

⚠️ Research & educational purposes only. This entry documents preclinical findings and does not constitute medical advice or a dosing recommendation. Always consult a qualified healthcare provider before beginning any protocol.

Side Effects & Safety

Because no human trials of KP1 or KP6 have been conducted, the human side-effect profile is unknown. The following are theoretical or preclinical observations, not a characterized human safety profile:

No human safety data at any dose — the full human adverse-event profile is undefined.
Inverted dose-response concern — for the cognitive endpoint, high dose was ineffective or potentially counterproductive; the safety of higher doses is uncharacterized.
Phosphate/calcium homeostasis — Klotho regulates phosphate and calcium; exogenous administration could theoretically disrupt mineral metabolism.
Injection-site reactions — theoretical for any injected peptide.
Unknown long-term effects — no chronic human exposure data exists.

Contraindications / cautions: Pregnancy, breastfeeding, hormone-sensitive conditions, existing kidney mineral imbalance. Products sold as "Klotho supplements" generally do not contain Klotho peptides and should not be assumed to carry these risks or benefits. Always consult a qualified healthcare provider before beginning any protocol.

Research Basis

KP1 — Kidney Fibrosis (Yuan et al., 2022)

In the foundational study published in Nature Communications (2022), KP1 was administered by intravenous injection in a mouse unilateral ureteral obstruction (UUO) kidney fibrosis model. KP1 showed preferential accumulation in injured kidneys, preserved kidney function, repressed TGF-β signaling, ameliorated renal fibrosis, and restored endogenous Klotho expression. KP1 has also been studied in ischemia-reperfusion injury models, where it inhibited cellular senescence in the fibrotic kidney by restoring Klotho expression via posttranscriptional regulation.

KP6 — Diabetic Kidney Disease (Zhou et al., 2022)

In the study published in Kidney International (2022), KP6 was administered by chronic infusion in STZ-induced type 1 and db/db type 2 diabetic mouse models over multiple weeks. KP6 reversed proteinuria, attenuated glomerular hypertrophy, mitigated podocyte damage, and ameliorated fibrotic lesions. A scrambled-sequence control peptide showed no therapeutic effect, confirming the activity is sequence-specific.

Full-length Klotho Protein — Cognitive Enhancement (Castner et al., 2023)

In Nature Aging (2023), a single systemic injection of low-dose Klotho protein (the full KL1 domain, not the short KP1/KP6 peptides) enhanced cognition in aged rhesus macaques within ~4 hours, with effects persisting ~2 weeks. Notably, low dose enhanced cognition; high dose did not — an inverted dose-response that complicates any translation to human dosing.

Mechanisms & Therapeutic Potential (Prud'homme et al., 2026)

A comprehensive review in Cells (2026) documents Klotho's multifaceted anti-aging actions: anti-fibrotic effects via TGF-β and Wnt inhibition (protecting kidneys, heart, lungs, liver); anti-inflammatory effects via NLRP3 inflammasome, NF-κB, and ROS suppression; reduction of cellular senescence and oxidative stress; neuroprotection against Aβ toxicity; and tumor-suppressor activity in breast, pancreatic, colon, and liver cancers.

Limitations preventing human translation

No human pharmacokinetic data — metabolism, distribution, and receptor binding in humans are unknown.
Species differences — peptide behavior may differ significantly between rodents and humans.
Route challenges — IV injection and chronic infusion used in preclinical studies require adaptation for any clinical use.
Dose-response poorly characterized — even in animal models, and inverted for the cognitive endpoint.
Peptide stability — in vivo half-life and proteolytic degradation rates are not formally established.

⚠️ Research & educational purposes only. Not medical advice.